116 related articles for article (PubMed ID: 2891797)
1. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Ogawa M; Kimura I; Tominaga S
J Clin Oncol; 1988 Jan; 6(1):128-41. PubMed ID: 2891797
[TBL] [Abstract][Full Text] [Related]
2. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia.
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Tominaga S; Tsugane S; Minato K
J Clin Oncol; 1988 Jul; 6(7):1088-97. PubMed ID: 2899140
[TBL] [Abstract][Full Text] [Related]
3. Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ogawa M; Tominaga S; Tsugane S; Minato K
Jpn J Clin Oncol; 1988 Jun; 18(2):113-24. PubMed ID: 3379782
[TBL] [Abstract][Full Text] [Related]
4. [A comparative study of VEPA and ACOMEP-BD regimen for the patients with non-Hodgkin's lymphoma].
Kanamori H; Tanabe J; Okamoto R; Tamura T; Fujita H; Murata T; Hashimoto Y; Harano H; Matsuzaki M; Motomura S
Rinsho Ketsueki; 1993 Jun; 34(6):697-704. PubMed ID: 8366571
[TBL] [Abstract][Full Text] [Related]
5. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
Chubachi A; Miura AB; Yamaguchi A; Nishimura S
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
[TBL] [Abstract][Full Text] [Related]
6. [Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (VEPA) for non-Hodgkin's lymphoma].
Saaki A; Yokomatsu Y; Kojima K; Yoshikawa T; Sannomiya Y; Tatsumi J; Hashimoto K; Park K; Kawarabayashi K; Yoshikawa C
Gan To Kagaku Ryoho; 1986 Jan; 13(1):65-9. PubMed ID: 3753642
[TBL] [Abstract][Full Text] [Related]
7. [VEPA and ML-Y1 regimen for elderly non-Hodgkin's lymphoma].
Tanabe J; Kanamori H; Matsuzaki M; Motomura S; Mohri H; Okubo T; Maruta A; Kodama F
Nihon Ronen Igakkai Zasshi; 1994 Feb; 31(2):135-41. PubMed ID: 7517465
[TBL] [Abstract][Full Text] [Related]
8. [Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy].
Hattori M; Motomura S; Tomita N; Taguchi J; Tanabe J; Sakai R; Fujisawa S; Fukawa H; Kanamori H; Mouri H; Maruta A; Kodama F; Okubo T
Rinsho Ketsueki; 1996 Feb; 37(2):101-8. PubMed ID: 8852026
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
Kinoshita T; Hotta T; Tobinai K; Kobayashi T; Ishizuka N; Tomonaga M; Sai T; Ohno Y; Kasai M; Ogura M; Mikuni C; Toki H; Sano M; Masaki Y; Ohtsu T; Matsuno Y; Takenaka T; Shirakawa S; Shimoyama M;
Int J Hematol; 2004 Nov; 80(4):341-50. PubMed ID: 15615259
[TBL] [Abstract][Full Text] [Related]
10. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group.
Kobayashi T; Tobinai K; Shimoyama M; Mikuni C; Konda S; Kozuru M; Araki K; Sai T; Fukuhara S; Matsumoto M; Aoki I; Deura K; Oyama A; Hotta T; Abe T; Toki H; Nagai M; Fukuda H; Niimi M; Yamaguchi N; Tajima K; Shirakawa S
Jpn J Clin Oncol; 1999 Jul; 29(7):340-8. PubMed ID: 10470659
[TBL] [Abstract][Full Text] [Related]
12. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203.
Mizoroki F; Hirose Y; Sano M; Fukuda H; Tobinai K; Nakata M; Taniwaki M; Kawano F; Uozumi K; Sawada K; Fukuhara S; Nasu K; Ohno Y; Toki H; Togawa A; Kikuchi M; Hotta T; Shimoyama M;
Int J Hematol; 2006 Jan; 83(1):55-62. PubMed ID: 16443554
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of 82 patients with non-Hodgkin's lymphoma--mainly on the evaluation of therapeutic efficacy].
Kakinoki Y; Maekawa I; Kawamura T; Miyake T; Kurosawa M; Okabe M; Kamiya K; Sasaki O
Hokkaido Igaku Zasshi; 1987 Dec; 62(6):841-50. PubMed ID: 3443427
[TBL] [Abstract][Full Text] [Related]
17. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Cooper IA; Wolf MM; Robertson TI; Fox RM; Matthews JP; Stone JM; Ding JC; Dart G; Matthews J; Firkin FC
J Clin Oncol; 1994 Apr; 12(4):769-78. PubMed ID: 7512131
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Teodorovic I; Pittaluga S; Kluin-Nelemans JC; Meerwaldt JH; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk EM; Peeters CD
J Clin Oncol; 1995 Nov; 13(11):2819-26. PubMed ID: 7595744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
